A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HALO-EM
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 07 Jun 2017 According to a Teva Pharmaceuticals media release, results from this and another trial in chronic migraine will be presented at the Congress of the International Headache Society (IHC) later this year. Based on the results of this and the chronic migraine trial, Teva plans to submit a Biologics License Application to the US FDA for fremanezumab later this year in both episodic and chronic migraine.
    • 07 Jun 2017 Results published in a Teva Pharmaceuticals media release.
    • 07 Jun 2017 Primary endpoint (Mean change from baseline in the monthly average number of migraine days) has been met according to a Teva Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top